What antiarrhythmic can be used in the treatment of ventricular tachycardia?

Lidocaine is considered a key antiarrhythmic medication used specifically for the treatment of ventricular tachycardia (VT), particularly in the setting of ischemic heart disease. It works by blocking sodium channels, which helps to stabilize the myocardial membrane and prevent the rapid depolarization that characterizes tachycardia. By suppressing abnormal electrical activity in the heart, Lidocaine can effectively convert VT to a normal sinus rhythm, making it an important agent in acute care settings, especially during cardiac arrest or in post-myocardial infarction scenarios.

Other options, while benefits may exist in specific contexts, do not primarily serve the role of treating ventricular tachycardia. Adenosine is generally utilized for terminating paroxysmal supraventricular tachycardia rather than VT. Aspirin is an antiplatelet medication often used in the prevention of myocardial infarction but does not have an antiarrhythmic effect. Magnesium can play a role in the management of certain types of arrhythmias (like Torsades de Pointes) and may have a supportive role in the treatment of arrhythmias related to electrolyte imbalances, but it is not a primary treatment for ventricular tachycardia. Thus,